S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
The Next Big Crisis Is Here (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
The Next Big Crisis Is Here (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
The Next Big Crisis Is Here (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
The Next Big Crisis Is Here (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
NASDAQ:ELEV

Elevation Oncology - ELEV Stock Forecast, Price & News

$1.02
-0.02 (-1.92%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.01
▼
$1.04
50-Day Range
$0.75
▼
$1.16
52-Week Range
$0.72
▼
$5.20
Volume
11,675 shs
Average Volume
171,481 shs
Market Capitalization
$23.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.83

Elevation Oncology MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
471.9% Upside
$5.83 Price Target
Short Interest
Healthy
0.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.02mentions of Elevation Oncology in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.97) to ($2.25) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

150th out of 1,055 stocks

Biological Products, Except Diagnostic Industry

26th out of 170 stocks

See Top Rated MarketRank™ Stocks Here

ELEV stock logo

About Elevation Oncology (NASDAQ:ELEV) Stock

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Receive ELEV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter.

ELEV Stock News Headlines

January 25, 2023 | marketbeat.com
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks? (ELEV)
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.
January 27, 2023 | americanbankingnews.com
Wedbush Analysts Raise Earnings Estimates for Elevation Oncology, Inc. (NASDAQ:ELEV)
January 28, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
January 26, 2023 | seekingalpha.com
ELEV Elevation Oncology, Inc.
January 26, 2023 | americanbankingnews.com
Brokers Offer Predictions for Elevation Oncology, Inc.'s FY2027 Earnings (NASDAQ:ELEV)
January 24, 2023 | americanbankingnews.com
Elevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Update
January 9, 2023 | finance.yahoo.com
Elevation Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 7, 2023 | msn.com
Elevation Oncology CEO resigns as part of company prioritization effort
January 28, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
January 6, 2023 | finance.yahoo.com
Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021 and CEO Transition
November 30, 2022 | finance.yahoo.com
Elevation Oncology to Participate at the JMP Securities Hematology and Oncology Summit
November 3, 2022 | finance.yahoo.com
Elevation Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
August 4, 2022 | finance.yahoo.com
Merrimack Reports Second Quarter 2022 Financial Results
August 3, 2022 | finance.yahoo.com
Elevation Oncology to Participate at the Wedbush PacGrow Healthcare Conference
July 30, 2022 | morningstar.com
Elevation Oncology Inc Stock News
July 12, 2022 | uk.investing.com
Elevation Oncology Inc (ELEV)
July 12, 2022 | uk.investing.com
Short Volatility Alert: Elevation Oncology, Inc.
May 27, 2022 | uk.investing.com
Why Elevation Oncology Stock Is Rising
May 27, 2022 | barrons.com
Elevation Oncology Inc.
May 27, 2022 | morningstar.com
Elevation Oncology Gets Fast Track Designation for Seribantumab to Treat Tumors Harboring NRG1 Gene Fusions
May 26, 2022 | finance.yahoo.com
Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022
May 26, 2022 | finance.yahoo.com
Estimating The Intrinsic Value Of Elevation Oncology, Inc. (NASDAQ:ELEV)
May 25, 2022 | msn.com
Elevation Oncology Shares Gain On FDA Fast Track Designation For Seribantumab In Tumor-Agnostic Settings
May 25, 2022 | seekingalpha.com
Elevation gets FDA fast track status for seribantumab to treat gene-specific solid tumors
May 25, 2022 | finance.yahoo.com
Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene Fusions
May 5, 2022 | apnews.com
Merrimack Reports First Quarter 2022 Financial Results
May 5, 2022 | finance.yahoo.com
Elevation Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
See More Headlines
Receive ELEV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter.

ELEV Company Calendar

Last Earnings
11/03/2022
Today
1/28/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ELEV
CUSIP
N/A
CIK
1783032
Web
www.elevationoncology.com
Phone
716-371-1125
Fax
N/A
Employees
23
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.83
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+471.9%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.68)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-32,040,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-78.52%
Return on Assets
-66.01%

Debt

Debt-to-Equity Ratio
0.44
Current Ratio
7.29
Quick Ratio
7.29

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.06 per share
Price / Book
0.17

Miscellaneous

Outstanding Shares
23,300,000
Free Float
19,340,000
Market Cap
$23.77 million
Optionable
Not Optionable
Beta
0.30

Key Executives

  • Dr. Shawn M. Leland Pharm.D. (Age 38)
    R.Ph., Founder, Pres, CEO & Director
    Comp: $737.97k
  • Mr. Joseph J. Ferra Jr. (Age 46)
    Chief Financial Officer
    Comp: $391.52k
  • Ms. Valerie Malyvanh Jansen M.D. (Age 44)
    Ph.D., Chief Medical Officer
    Comp: $476.7k
  • Ms. Tammy Furlong CPA
    P.M.P., VP of Fin. & Accounting and Sec.
  • Dr. David Dornan Ph.D. (Age 44)
    Chief Scientific Officer
  • Candice Masse
    Sr. Director of Corp. Communications & Investor Relations
  • Mr. Robert C. Yang
    VP of Legal Affairs
  • Mr. Brian Sullivan
    VP of Corp. Devel.
  • Mr. Ryan Bloomer
    Head of CMC

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ELEV Stock - Frequently Asked Questions

Should I buy or sell Elevation Oncology stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elevation Oncology in the last twelve months. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ELEV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ELEV, but not buy additional shares or sell existing shares.
View ELEV analyst ratings or view top-rated stocks.

What is Elevation Oncology's stock price forecast for 2023?

4 analysts have issued 1-year price targets for Elevation Oncology's stock. Their ELEV share price forecasts range from $2.00 to $8.00. On average, they anticipate the company's stock price to reach $5.83 in the next twelve months. This suggests a possible upside of 471.9% from the stock's current price.
View analysts price targets for ELEV or view top-rated stocks among Wall Street analysts.

How have ELEV shares performed in 2023?

Elevation Oncology's stock was trading at $0.95 at the beginning of the year. Since then, ELEV stock has increased by 7.4% and is now trading at $1.02.
View the best growth stocks for 2023 here.

Are investors shorting Elevation Oncology?

Elevation Oncology saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 33,700 shares, a decrease of 29.4% from the December 31st total of 47,700 shares. Based on an average daily volume of 81,000 shares, the short-interest ratio is currently 0.4 days. Approximately 0.2% of the shares of the stock are sold short.
View Elevation Oncology's Short Interest.

When is Elevation Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our ELEV earnings forecast.

How were Elevation Oncology's earnings last quarter?

Elevation Oncology, Inc. (NASDAQ:ELEV) posted its earnings results on Thursday, November, 3rd. The company reported ($1.67) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by $0.55.

When did Elevation Oncology IPO?

(ELEV) raised $1 billion in an initial public offering on Friday, June 25th 2021. The company issued 63,000,000 shares at a price of $15.00-$17.00 per share.

What is Elevation Oncology's stock symbol?

Elevation Oncology trades on the NASDAQ under the ticker symbol "ELEV."

How do I buy shares of Elevation Oncology?

Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Elevation Oncology's stock price today?

One share of ELEV stock can currently be purchased for approximately $1.02.

How much money does Elevation Oncology make?

Elevation Oncology (NASDAQ:ELEV) has a market capitalization of $23.77 million. The company earns $-32,040,000.00 in net income (profit) each year or ($3.68) on an earnings per share basis.

How can I contact Elevation Oncology?

The official website for the company is www.elevationoncology.com. The company can be reached via phone at 716-371-1125 or via email at ir@elevationoncology.com.

This page (NASDAQ:ELEV) was last updated on 1/28/2023 by MarketBeat.com Staff